Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study

Authors

Zhigang Bai (ORCID: https://orcid.org/0000-0001-9234-9354)
Jiegao Zhu (ORCID: https://orcid.org/0000-0001-9747-6563)
Xiaobao Yang (ORCID: https://orcid.org/0000-0001-5266-7673)
Wei Guo (ORCID: https://orcid.org/0000-0002-9158-8107)
Kuinan Tong (ORCID: https://orcid.org/0009-0005-5706-8342)
Wei Deng (ORCID: https://orcid.org/0000-0001-5313-5599)
Kun Liu (ORCID: https://orcid.org/0000-0001-5807-0501)
Zhongtao Zhang (ORCID: https://orcid.org/0000-0002-8291-4097)
Hongwei Wu (ORCID: https://orcid.org/0009-0001-0987-4391)
Chao Jing (ORCID: https://orcid.org/0000-0002-2146-3448)

Institutions

Capital Medical University (CN)
National Clinical Research Center for Digestive Diseases (CN)
Beijing Friendship Hospital (CN)

Publication Details

Journal: The Oncologist
Published: 2024-08-05
DOI: https://doi.org/10.1093/oncolo/oyae154
Citations: 2
Primary Topic: Cholangiocarcinoma and Gallbladder Cancer Studies
Type: article
Field-Weighted Citation Impact: 1.15

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study

Zhigang Bai, Jiegao Zhu, Xiaobao Yang, Wei Guo et al.

Aug 5, 2024

2 citations

The Oncologist

Cholangiocarcinoma and Gallbladder Cancer Studies

1.15

article

Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study

Zhigang Bai, Jiegao Zhu, Xiaobao Yang, Wei Guo, Kuinan Tong, Wei Deng, Kun Liu, Zhongtao Zhang, Hongwei Wu, Chao Jing

August 5, 2024article en

2 citations

Abstract

No abstract available for this paper.

The OncologistVol. 29(11)

Capital Medical University (CN), National Clinical Research Center for Digestive Diseases (CN), Beijing Friendship Hospital (CN)

Good health and well-being

Openalex Percentile: Top 21%

Cholangiocarcinoma and Gallbladder Cancer Studies

1.15

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study — Zhigang Bai, Jiegao Zhu, et al. · The Oncologist (2024) | TGRS Research Map | TGRS